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Purpose: Contamination of pharmaceuticals with microorganisms irrespective whether they 
are harmful or nonpathogenic can bring about changes in physicochemical characteristics of 
the medicines. Although sterility is not a requirement in official compendia for nonsterile phar-
maceuticals, bioburdens need to be within acceptable limits. Therefore, this study investigated 
microbial contamination of 10 nonsterile pharmaceuticals frequently delivered to outpatients 
by identifying and quantifying microbial contaminants and susceptibility pattern testing on the 
microbes isolated.
Methods: The study was carried out at Amana Municipal Hospital in Dar es Salaam, Tanzania. 
The protocol for the study involved structured selection of representative tablets, syrups, and 
capsules from the hospital’s outpatient pharmacy. Constitutive microorganisms were elaborated 
and enumerated using standard microbiologic procedures.
Results: Results showed that 50% of all tested products were heavily contaminated, and the 
predominant contaminants comprised Klebsiella, Bacillus, and Candida species. Furthermore, 
the results showed that the isolated Bacillus and Klebsiella species were resistant to   Augmentin® 
and cloxacillin. The differences in means for cfu/mL and zones of inhibition among the micro-
organisms isolated were considered significant at P , 0.05.
Conclusion: The nonsterile pharmaceuticals were presumably microbiologically contaminated 
due to poor handling during dispensing, repackaging, and/or nonadherence to good manufactur-
ing practice. Therefore, training and educating the dispensers, as well as patients, on the proper 
handling and use of medicines cannot be overemphasized, because these are key aspects in 
controlling cross-contamination of medicines.
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Introduction
Pharmaceuticals are used in a variety of ways in the prevention, treatment, and diag-
nosis of diseases. In recent years, manufacturers of pharmaceuticals have improved 
the quality of nonsterile pharmaceuticals such that today such products contain only 
minimal bioburden.1 The occurrence of microbial contamination has been well docu-
mented, and contaminants range from true pathogens such as Clostridium tetani, to 
opportunistic pathogens such as Pseudomonas aeruginosa.2 Several reports have also 
been published describing clinical hazards that are attributable to microbiologically 
contaminated pharmaceuticals.3–5 The major health concern is when such microbial 
contaminants exceed acceptable limits (102 cfu/mL).6 It must be stressed, however, 
that the majority of cases of medicine-related infections are probably not recognized 
or reported as such.7Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Solid dosage forms, mainly tablets and capsules, constitute 
a large proportion of medicines which are dispensed in 
Tanzanian hospitals. Although many now are presented in 
blister packs, most developing countries, including   Tanzania, 
still have instances where such medicines are supplied in 
bulk containers, with the prescribed amount being drawn 
from these containers.8 Mishandling may result in a serious 
health hazard following ingestion of highly contaminated 
drugs/solid dosage forms by patients whose immunity is 
already compromised by illness. The presence of microbes 
in drugs not only makes them hazardous from the infectious 
standpoint, but may also change the physical, chemical, and 
organoleptic properties of the drugs, alter the contents of 
active ingredients, or convert them to toxic products.9 Thus, 
a medicine may be considered microbiologically spoiled in 
this situation, depending on its intended use. The presence 
of even a low level of acutely pathogenic microorganisms, 
higher   levels of opportunist pathogens, or toxic microbial 
metabolites that persist even after death of the original 
contaminants may render the product ineffective. Physico-
chemical deterioration as a consequence of microbial growth 
is a satisfactory reason to consider the product unsafe for 
human use.9
Microbial infections are not only the result of the   physical 
presence of microorganisms, but also their metabolites/
toxins that become harmful even if they are found in minute 
quantities.10 Some of these toxin-related illnesses include 
acute gastroenteritis, abdominal discomfort, and diarrhea. 
Symptoms vary from mild gastric distress to death, depending 
on individual susceptibility to the toxin, amount of ingested 
toxin, and general health of the victim.10,11 Severe   infections 
in immunocompromised persons have been attributed to 
Bacillus and Klebsiella spp.11 Several hospital acquired 
and some community-acquired infections, in particular 
  pneumonia, are also ascribed to Klebsiella spp.12
Solid dosage forms (capsules or tablets) are prone to 
microbial spoilage or degradation. The more serious   problem 
arising from microbial contamination of solid dosage forms is 
the absence of obvious signs of spoilage. Therefore, there is 
a need to know the microbial content of all drugs and medi-
cines, whether they are sterile or nonsterile.13 Previous   studies 
have demonstrated microbiologic quality concerns with 
regard to both commercially available and   extemporaneously 
prepared pharmaceuticals, storage, and sale of expired liquid 
disinfectants.5,14,15 This has compelled us to embark on this 
study in order to assess the magnitude of such microbial con-
taminants in nonsterile   pharmaceuticals given to   outpatients 
at Amana Municipal Hospital in Dar es Salaam.
Material and methods
study design and area
This was a cross-sectional study conducted at Amana Municipal 
Hospital in Dar es Salaam between December 2007 and April 
2008. The hospital is centrally located within Dar es Salaam, 
the largest city in the region, with over four million habitants. 
Thus, Amana Municipal Hospital receives patients from 
all parts of the city and beyond. Amana Municipal Hospital 
contains one outpatient pharmacy which is run by several 
pharmacists, pharmacy interns, pharmaceutical technicians, 
and assistants.
sample collection and preparation  
of sample dispersions
Five unit samples each of paracetamol, aspirin, vitamin B 
complex, and ferrous sulfate tablets, as well as   indomethacin, 
doxycycline, and amoxicillin capsules, were randomly 
sampled from containers of 1000 tablets/capsules.   Tablets, 
capsules, and syrups constitute a large proportion of 
the medicines on the market, are dispensed in all health 
facilities, and are prone to microbial contamination under 
improper storage conditions. The selected drug samples are 
representative products that are readily available and most 
commonly used in the community. Two sample bottles each 
of Glycodin® cough syrup (Alembic, India) and Broncolin 
Paediatric® cough syrup (Interchem, Tanzania) were also 
randomly picked from the shelves. Two 100 mL aliquots of 
Eusol (Edinburgh University solution of lime, liquid disin-
fectant) were also drawn from a large vessel which was used 
for extemporaneous preparation of the disinfectant. Label 
information (batch number, expiry date, manufacturing date, 
directions for use, and ingredient composition) was recorded 
(Table 1). The collected samples of each brand were ground 
and/or dispersed in 10 mL of sterile normal saline by gentle 
agitation. Similarly, 2 mL of the cough syrup and Eusol 
solution were each dispersed in 8 mL of sterile normal saline 
and made up to a volume of 10 mL. All dispersions were 
left to settle for five minutes to dislodge possible microbial 
cells and to separate the solid particles and supernatants to 
be used in further tests. Sterile normal saline was used as a 
negative control.
Isolation and quantification of microbial 
contaminants
Selective and nonselective culture media were used for 
quantification and isolation of the microbial contaminants, 
ie, nutrient agar (Oxoid, England), Sabouraud’s dextrose Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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agar (Pronadisa, Spain), thiosulfate-citrate-bile-sucrose agar, 
and MacConkey agar (Roth, Germany). A 1 mL aliquot of 
each dispersion was directly spread-plated onto the sterile 
  nutrient agar and Sabouraud’s dextrose agar, and incubated 
for 24–48 hours at 37°C, thus facilitating the quantification 
of yeast cells rather than the mycelia forms that grow better 
at lower temperatures.16 Prior to observation and recording of 
any microbial contamination, serial dilution of the dispersed 
tablet/capsule was performed whenever deemed necessary. 
Quantification of viable microbial counts was conducted and 
expressed as cfu/mL. Pure and single microbial colonies were 
subcultured onto solid and liquid media, incubated at 37°C 
for 24 hours, and the substantive isolates were finally stored 
at 4°C until further use.
Identification of microbiologic 
contaminants and antibiotic  
susceptibility profiling
Isolated microbial contaminants were subjected to standard 
microbiologic identification tests based on characteristic 
colony growth morphologies, and biochemical and physi-
ologic tests to confirm their identity/purity.16,17 Using What-
man® qualitative filter paper (Maidstone, UK), 5 mm discs 
were punched and five concentrations (0.1, 0.05, 0.02, 0.01, 
and 0.005 µg/mL) were prepared for each of the antifungal 
agents, fluconazole and ketoconazole (Remedica, Cyprus). 
These were unavailable in the form of discs. For antibacte-
rial agents, discs comprising Augmentin® 10 µg, cloxacillin 
5 µg, levofloxacillin 25 µg, ceftriaxone 10 µg, tetracycline 
10 µg, and ampicillin 10 µg were purchased and used in the 
assay. The stored microbes were sensitized and compared 
with standard turbidity (McFarland 0.5 M) prior to subjecting 
them to susceptibility tests on RPMI–glucose agar and Muller 
Hinton agar for fungal and bacterial isolates,   respectively, 
using the disc diffusion method.17,18 Reference strains, 
ie, Staphylococcus aureus (ATCC 25923) and Candida 
albicans (ATCC 90028) were included as control microor-
ganisms. Following overnight incubation at 37°C, diameter 
zones of inhibition (ZI) were determined and interpreted as 
susceptible, intermediate, or resistant for each of the assayed 
drugs, as previously described.16–18
Data analysis
Each of the above assays was performed twice in tripli-
cate for consistency of results and statistical purposes. The 
obtained data were analyzed using the Statistical Package for 
Social Sciences (version 15.0, 1999) software (SPSS Inc., 
Chicago, IL). Differences in means for cfu/mL and ZI among 
isolated microorganisms were compared using the t-test and 
considered significant at P , 0.05.
Results
Assessment of microbiologic quality
In this study, a total of 10 different nonsterile pharmaceuticals 
delivered to patients in the hospital were examined for micro-
bial contamination, and the isolated microbes were subjected 
to susceptibility tests. The results indicated that all assayed 
samples (n = 10) showed microbial growth, hence were 
microbiologically contaminated. Results showed that indo-
methacin capsules and Glycodin cough syrup were the most 
heavily contaminated, showing a bacterial load of 4.8 × 103 
and 6.0 × 103 cfu/mL, respectively. Ferrous sulfate tablets 
exhibited a bacterial load of 1.72 × 103 cfu/mL. A Eusol 
solution was also contaminated with Bacillus spp, Candida 
spp, Aspergillus spp, and Klebsiella spp (Table 2).
Antibiotic susceptibility profiling
Bacillus spp were found to be resistant to augmentin 10 µg 
and cloxacillin 5 µg, which are some of the commonly used 
antibiotics for treatment of bacterial infections, particularly 
Table 1 Label information and sources of analyzed pharmaceuticals
Product type Brand/active ingredient Manufacture date Expiry date Manufacturer Batch no.
Tablet Paracetamol May 2007 April 2011 shellys, Tz 7294
Tablet Aspirin Oct 2005 sept 2008 shellys, Tz 8159
Tablet Vitamin B complex July 2007 June 2011 shellys, Tz 7026
Tablet Ferrous sulfate June 2007 May 2009 simrone, india 776
Capsule indomethacin Jan 2007 Dec 2009 simrone, india 315
Capsule Doxycycline Dec 2006 nov 2008 Keko, Tz 0269
Capsule Amoxicillin Dec 2007 nov 2008 Keko, Tz 087
PC syrup Broncolin Paediatric® May 2007 April 2009 interchem, Tz POs7030
Cough syrup glycodin® June 2007 May 2010 Alembic, india 7201014he
Disinfectant eusol Jan 2007 Dec 2007 interchem, Tz eUs7012
Abbreviations: PC, Pediatric cough syrup; Tz, Tanzania.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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those due to Gram-negative bacterial infections (Table 3). 
Klebsiella spp and Candida spp were fairly susceptible to 
the tested antimicrobial agents as shown in Table 4. The 
antifungal drug susceptibility patterns were interpreted as per 
recommendations,16–18 and none of the fungal contaminants 
were resistant to the tested drugs (Table 4).
Discussion
The study findings have shown that all tested samples were 
microbiologically contaminated. The isolated aerobic bacteria 
were mainly Bacillus spp, while the fungal contaminants 
comprised Candida spp and Aspergillus spp. Our findings 
are consistent with those of previous studies, which found 
that the majority of microbial contaminants in nonsterile 
pharmaceuticals are Bacillus spp, C. albicans, Aspergillus 
spp, and Klebsiella spp.4 The present study revealed a biobur-
den up to 10-fold of the acceptable limits (,102 cfu/mL) in 
these final products.6,16 However, the presence of potentially 
pathogenic and opportunistic microorganisms like Aspergil-
lus and Klebsiella spp or their byproducts is occasionally 
not desirable.13 About 50% (5/10 samples) surpassed the 
bioburden limit of 102 cfu/mL. This calls for more stringent 
measures to prevent possible detrimental effects. This is an 
indication of improper handling of pharmaceutical products 
in our hospital pharmacies, as already reported elsewhere.4
The majority of the microorganisms isolated from the 
samples were normal human flora, which are widely distrib-
uted in nature with the exception of the Aspergillus spp.10 
This suggests that these medicines were microbiologically 
contaminated as a result of improper handling, poor hygienic 
procedures during repackaging into smaller packs, and dis-
pensing of medicines. The presence of potentially pathogenic 
opportunistic microbes, including Aspergillus spp and C. 
albicans, cannot be overemphasized, because they may cause 
a significant deterioration in the health status of patients, 
particularly those who are immunologically compromised, 
and of infants with an immature immune system.10,11
The microbiologic quality of nonsterile solid dosage 
forms, like tablets, is dependent on the bioburden of the raw 
materials, both in the active ingredients and excipients.1,19 
Hence, the failure of strict observation of good manufactur-
ing practice at any stage of production may greatly affect 
the microbiologic quality of the end products.19 Moreover, 
under tropical conditions, as in Tanzania, which has an aver-
age temperature of 31°C and high average relative humidity, 
inadequately stored pharmaceuticals become prone to micro-
bial spoilage.9 Regarding the susceptibility tests, the bacteria 
isolated (Bacillus and Klebsiella spp) were found to be sus-
ceptible to most of the assayed antibiotics, with the exception 
of cloxacillin and augmentin. Failure of augmentin, which is 
a β-lactamase enzyme inhibitor, is of major concern due to 
the fact that, Bacillus and Klebsiella spp could be extended 
spectrum β-lactamase producers.20,21 Because of widespread 
drug resistance worldwide, the observed drug-resistant 
microbial contaminants in the present study underscore a 
Table 2 Isolated and identified microbial contaminants
Item Viable counts (cfu/mL)
Bacillus  
spp
Candida  
spp
Aspergillus  
spp
Klebsiella   
spp
Paracetamol  
tablets
9 – – 1.9 × 102
Ferrous sulphate  
tablets
1.72 × 103 4.3 × 102 – –
Aspirin tablets 4.0 × 101 3.2 × 102 – –
Vitamin B  
complex tablets
2.3 × 101 6 3 –
indomethacin  
capsules
– – – 4.8 × 103
Doxycycline  
capsules
4.7 × 102 – – –
glycodin® syrup 2.5 × 101 2 – 6.0 × 103
Broncolin  
Paediatric®
5 – 1 –
Amoxycillin  
capsules
– 6.0 × 101 – –
eusol solution – 7 – –
Abbreviations: cfu, colony forming units; spp, species.
Table 3 susceptibility patterns of isolated bacterial contaminants
Drug name Diameter of ZI (mm) Comment
Bacillus  
spp
Klebsiella  
spp
Reference 
S. aureus
Augmentin® 10 µg – – 12 R
Tetracycline 10 µg 22 20 20 s
Cloxacillin 5 µg – – 15 R
Ampicillin 10 µg 20 14 24 s
Levofloxacillin 25 µg 30 34 30 s
Ceftriaxone 10 µg 32 16 34 s
Abbreviations:  s,  sensitive;  r,  Resistant;  spp,  species;  S.  aureus,  Staphylococcus 
aureus; Zi, zones of inhibition.
Table 4 susceptibility patterns of Candida albicans (contaminants) 
to antifungal agents 
Concentration 
(μg/mL)
Diameter of ZI (mm) Comment
Fluconazole Ketoconazole
0.1 52 41 s
0.05 48 40 s
0.02 44 40 s
0.01 44 38 s
0.005 40 37 s
Abbreviations: s, sensitive; Zi, zones of inhibition.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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need for immediate and more strict measures to address the 
situation by adhering to rational usage of antibiotics in our 
communities.22 Ingestion of such drug-resistant microorgan-
isms by an individual whose immune system is suppressed 
may result in aggravation of illness as a consequence of 
secondary infection.10 Pathogenic microorganisms become 
problematic when they outnumber the normal flora, and this 
is when they begin to create health problems.23 However, the 
Candida spp isolated, although found to be susceptible to both 
fluconazole and ketoconazole, are opportunistic pathogens 
known to cause potentially fatal deterioration of health status 
in immunocompromised individuals.24
Bacillus species are ubiquitous, but undesirable because 
of their spoilage potential, and their presence in a product 
suggests poor environmental hygiene during processing or 
heavily contaminated or adulterated raw materials.11,25 On the 
other hand, Klebsiella spp are found in the respiratory, 
  intestinal, and urinogenital tracts of animals and humans. 
  However, when Klebsiella moves outside the gut, it can cause 
a serious infection. Thus, its presence in the assayed samples 
is also an indication of unhygienic conditions, and may have 
originated from pharmaceutical personnel.4,13 Consequently, 
compliance with aseptic techniques during preparation of 
pharmaceuticals, and education on personal hygiene for the 
personnel, may minimize microbial   cross-contamination, 
thus preventing spoilage of the products and possible 
  detrimental effects for patients.16,24 Failure to establish a 
direct correlation between the drug-resistant microbial con-
taminants isolated and their direct implications for patient 
health might be one of the drawbacks of the present study. 
Such a   finding would have elucidated the magnitude of 
pharmaceutical   contamination-related microbial infections in 
Tanzania. Nevertheless, having such a large proportion (6%) 
of the population living with human immunodeficiency virus/
acquired immunodeficiency syndrome, who unfortunately are 
also likely to be malnourished, the dangers of administration 
of such microbiologically contaminated products cannot be 
overestimated.26,27
Conclusion
This study has revealed heavy microbial contamination 
in 50% of pharmaceuticals dispensed at our hospital 
pharmacy. Klebsiella, Bacillus, and Candida spp are the 
predominant contaminants. Of the identified microbial 
contaminants, Bacillus spp were resistant to augmentin and 
cloxacillin. Poor handling of the pharmaceutical products 
during dispensing or repackaging might have contributed 
to the observed high rate of microbial contamination. 
Education on personal hygiene and proper handling of 
medicines in dispensers cannot be overemphasized, since 
these are essential for prevention and control of microbial 
contamination of pharmaceuticals and other medicine-
derived infections.
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